Aysha had been sick a lot. Her family also noticed she was losing weight even though her eating habits hadn’t changed. Then ...
The Food and Drug Administration Feb. 5 released an alert notifying patients of a safety concern using diabetes devices such ...
Hybrid closed loop technology was associated with superior efficacy and safety outcomes relative to standard insulin therapy in T1D.
Q1 2025 Earnings Call Transcript February 6, 2025 Embecta Corp. beats earnings expectations. Reported EPS is $0.65, ...
The US FDA warns users of smartphone-linked diabetes devices like CGMs and insulin pumps of potential health risks due to ...
Patients using diabetes apps can miss critical alerts. Here’s how to make sure you're getting them
Patients who use smartphone apps to manage their diabetes could face serious health problems if they miss notifications ...
Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...
There’s an ongoing push to improve health care affordability and reduce out-of-pocket costs, especially for prescription ...
Adjusted EBITDA margin increased to 37.2% from 25.2% in Q4 2024, driven by cost reductions and operational improvements. Management's tone shifted positively, highlighting stronger-than-expected ...
Medha N. Munshi, MD, a geriatrician and endocrinologist at Beth Israel Deaconess Medical Center, has dedicated her career to ...
Managing diabetes is even harder when temperatures and humidity are rising. Find out how extreme heat can negatively affect ...
During the fiscal year 2025 first quarter, the Company paid an aggregate principal amount of approximately $32.4 million outstanding under its term loan B facility that had an interest rate of 300 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback